相关实验视频

Updated: May 11, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

利图西马布对系统性红血性狼患者长期损伤的作用

Amanda da Silva Brito¹, Sofia Miranda², Teresa Moitinho de Almeida³

¹Serviço de Medicina Interna, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, Brazil1.

Rheumatology (Oxford, England)

|May 15, 2025

概括

利图西马布是一种B细胞耗尽疗法,是系统性红斑狼 (SLE) 的有效治疗方法. 虽然Rituximab治疗的患者最初显示出更多的损伤,但他们的长期损伤进展速度比标准疗法患者慢.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
临床医学临床医学

背景情况:

20多年来,B细胞枯竭疗法已用于系统性红斑狼 (SLE).
关于B细胞枯竭对SLE损伤进展的影响的研究有限.
利图西马布是一种关键的B细胞消耗疗法.

研究的目的:

评估Rituximab在减缓SLE患者损伤的有效性.
为了比较Rituximab治疗患者和接受标准免疫抑制疗法的对照组之间的损伤进展.

主要方法:

对380名SLE患者 (190名rituximab,190名对照人) 的回顾性分析,根据性别和发病年龄进行匹配.
使用系统性狼国际合作诊所/美国风湿病学院损害指数 (SLICC/ACR DI) 评估损害.
对111名患者进行二次分析,以评估DI进展.

主要成果:

接受Rituximab的患者最初的SLICC/ACR DI得分和抗dsDNA抗体标位较高.
群体之间的平均SLICC/ACR DI没有统计差异.
与对照组 (58.2%) 相比,rituximab组的损伤进展明显较慢 (44.2%).

结论:

利图西马布是SLE患者的可行的治疗选择,特别是那些患有耐火性或严重疾病的患者.
尽管最初的损伤较高,但Rituximab治疗导致长期损伤进展较慢.
用Rituximab治疗B细胞枯竭有效地管理SLE损伤累积.

关键词:

乙细胞枯竭剂的使用方法环酸胺的使用方法损害指数损害指数疾病的进展疾病的进展免疫抑制剂免疫抑制剂狼性炎是一种神经炎症.里图西马布 (Rituximab) 是一种药物.系统性红斑狼 (SLE) 是一种

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

相关概念视频

Rheumatic Heart Disease I: Introduction

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...